Menu
1 min read · estimated
APPROVED USE
What FDA approved
For adults with CLL or SLL after two or more treatment lines that included both a BTK inhibitor and a BCL-2 inhibitor.
LAMPGEN ANALYSIS
Why it matters
The accelerated approval added a noncovalent BTK inhibitor for patients exposed to both required classes.
What research teams should watch
Record individual prior lines and drug classes, and track the indication's confirmatory milestone.
PRIMARY RECORDS